Pharmacological Features and Therapeutic Implications of Plumbagin in Cancer and Metabolic Disorders: A Narrative Review
Open Access
Abstract
Plumbagin (PLB) is a naphthoquinone extracted from Plumbago indica. In recent times, there has been a growing body of evidence suggesting the potential importance of naphthoquinones, both natural and artificial, in the pharmacological world. Numerous studies have indicated that PLB plays a vital role in combating cancers and other disorders. There is substantial evidence indicating that PLB may have a significant role in the treatment of breast cancer, brain tumours, lung cancer, hepatocellular carcinoma, and other conditions. Moreover, its potent anti-oxidant and anti-inflammatory properties offer promising avenues for the treatment of neurodegenerative and cardiovascular diseases. A number of studies have identified various pathways that may be responsible for the therapeutic efficacy of PLB. These include cell cycle regulation, apoptotic pathways, ROS induction pathways, inflammatory pathways, and signal transduction pathways such as PI3K/AKT/mTOR, STAT3/PLK1/AKT, and others. This review aims to provide a comprehensive analysis of the diverse pharmacological roles of PLB, examining the mechanisms through which it operates and exploring its potential applications in various medical conditions. In addition, we have conducted a review of the various formulations that have been reported in the literature with the objective of enhancing the efficacy of the compound. However, the majority of the reviewed data are based on in vitro and in vivo studies. To gain a comprehensive understanding of the safety and efficacy of PLB in humans and to ascertain its potential integration into therapeutic regimens for cancer and chronic diseases, rigorous clinical trials are essential. Finally, by synthesizing current research and identifying gaps in knowledge, this review seeks to enhance our understanding of PLB and its therapeutic prospects, paving the way for future studies and clinical applications.Keywords
Funding Information
- Research in Unani Medicine (CCRUM), Ministry of AYUSH, Government of India (3-69/2020-CCRUM/Tech)
- Ajman University (3-69/2020-CCRUM/Tech)
This publication has 214 references indexed in Scilit:
- Natural compound plumbagin based inhibition of hIAPP revealed by Markov state models based on MD data along with experimental validationsProteins: Structure, Function, and Bioinformatics, 2024
- Anti-ovarian cancer actions and pharmacological targets of plumbaginNaunyn-Schmiedeberg's Archives of Pharmacology, 2023
- Investigating binding mechanism of thymoquinone to human transferrin, targeting Alzheimer's disease therapyJournal of Cellular Biochemistry, 2022
- 1,4‐Naphthoquinone: A Privileged Structural Framework in Drug Discovery2021
- Plumbagin protects the myocardial damage by modulating the cardiac biomarkers, antioxidants, and apoptosis signaling in the doxorubicin‐induced cardiotoxicity in ratsEnvironmental Toxicology, 2020
- Transferrin‐bearing liposomes entrapping plumbagin for targeted cancer therapyJournal of Interdisciplinary Nanomedicine, 2019
- MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradationMolecular Oncology, 2018
- Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre‐clinical studyThe Prostate, 2017
- Plumbagin Enhances Tamoxifen Sensitivity and Inhibits Tumor Invasion in Endocrine Resistant Breast Cancer through EMT RegulationPhytotherapy Research, 2016
- Antitubercular and Antibacterial Activity of Quinonoid Natural Products Against Multi‐Drug Resistant Clinical IsolatesPhytotherapy Research, 2013